natgillin/translations-raw huggingface dataset:
A potential pharmacodynamic interaction can also be expected with beta-blockers, calcium antagonists and digitalis.
Može se očekivati i potencijalna farmakodinamička interakcija s beta-blokatorima, antagonistima kalcija i digitalisom.
• ritonavir (a medicine for AIDS infection),
• ritonavir (lijek za AIDS infekciju),
EU/1/09/591/001 20 film-coated tablets EU/1/09/591/002 50 film-coated tablets EU/1/09/591/003 60 film-coated tablets EU/1/09/591/004 100x1 film-coated tablets
EU/1/09/591/001 20 filmom obloženih tableta EU/1/09/591/002 50 filmom obloženih tableta EU/1/09/591/003 60 filmom obloženih tableta EU/1/09/591/004 100x1 filmom obložena tableta
Very Common
Vrlo česte
A number of patients had been previously exposed to amiodarone (see section 4.4).
Određeni broj bolesnika prethodno je bio izložen amiodaronu (vidjeti dio 4.4).
In animal models, dronedarone reduces the heart rate.
U životinjskim modelima dronedaron usporava srčani ritam.
It is recommended to measure plasma creatinine values prior to and 7 days after initiation of dronedarone.
Preporučuje se izmjeriti vrijednosti kreatinina u plazmi prije početka liječenja i 7 dana nakon uvođenja dronedarona.
Interaction with warfarin and losartan (CYP 2C9 substrates) Warfarin and other vitamin K antagonists
Interakcija s varfarinom i losartanom (supstratima CYP2C9) Varfarin i drugi antagonisti vitamina
You and your doctor should decide if you will take MULTAQ or breastfeed.
Trebali biste odlučiti s Vašim liječnikom hoćete li uzimati MULTAQ ili dojiti.
Losartan and other Angiotensin II Receptor Antagonists (AIIRAs)
Losartan i drugi antagonisti receptora angiotenzina II
The DIONYSOS study compared the efficacy and safety of dronedarone (400 mg twice daily) versus amiodarone (600 mg daily for 28 days, then 200 mg daily thereafter) over 6 months.
Ispitivanje DIONYSOS uspoređivalo je djelotvornost i sigurnost dronedarona (400 mg dvaput na dan) i amiodarona (600 mg na dan tijekom 28 dana, a zatim 200 mg na dan) tijekom 6 mjeseci.
Dronedarone has vasodilatory properties, in coronary arteries (related to the activation of the nitric oxide pathway) and in peripheral arteries.
Dronedaron ima vazodilatatorska svojstva u koronarnim arterijama (povezana s aktivacijom puta dušikova oksida) te u perifernim arterijama.
After intravenous administration the volume of distribution at steady state (Vss) ranges from 1,200 to 1,400 L.
Nakon intravenske primjene volumen distribucije u stanju dinamičke ravnoteže (Vss) kreće se u rasponu od 1200 do 1400 l.
In patients, dronedarone and its metabolite are completely eliminated from the plasma within 2 weeks after the end of a 400 mg twice daily-treatment.
U bolesnika se dronedaron i njegov metabolit u potpunosti eliminiraju iz plazme unutar 2 tjedna po završetku liječenja dozom od 400 mg dvaput na dan.
It is recommended to monitor renal function periodically and to consider further investigations as needed.
Preporuča se periodično praćenje bubrežne funkcije te, prema potrebi, razmatranje daljnjih pretraga.
If no further increase in creatininaemia is observed, this value should be used as the new reference baseline taking into account that this may be expected with dronedarone.
Ako se ne uoči daljnje povećanje kreatininemije, izmjerenu vrijednost treba uzeti kao novu referentnu početnu vrijednost s obzirom da se takav razvoj događaja može očekivati kod primjene dronedarona.
In the event of overdose, treatment should be supportive and directed toward alleviating symptoms.
U slučaju predoziranja potrebno je uvesti potporno liječenje usmjereno prema ublažavanju simptoma.
Treatment with dronedarone should be stopped during the course of treatment, in case the patient develops any of the conditions which would lead to a contraindication as mentioned in section 4.3.
Primjenu dronedarona treba prekinuti tijekom liječenja ako se u bolesnika razvije bilo koje stanje koje bi moglo dovesti do neke od kontraindikacija navedenih u dijelu 4.3.
Although plasma exposure in elderly females was increased in a pharmacokinetic study conducted in healthy subjects, dose adjustments are not considered necessary (see sections 5.1 and 5.2).
Iako je u farmakokinetičkom ispitivanju provedenom u zdravih ispitanika utvrđena povećana izloženost u plazmi starijih žena, smatra se da nije potrebno prilagođavati dozu (vidjeti dio 5.1 i 5.2).
It can increase the blood levels of dronedarone and may increase your chance of getting side effects.
On može povisiti razinu dronedarona u krvi i može povećati mogućnost nastanka nuspojava.
Effect of other medicinal products on dronedarone
Učinak drugih lijekova na dronedaron
Assessment of intrinsic factors such as gender or age on the incidence of any treatment emergent adverse reactions showed an interaction for gender (female patients) for the incidence of any adverse reactions and for serious adverse reactions.
Procjena utjecaja intrinzičnih faktora poput spola i dobi na incidenciju svih nuspojava povezanih s liječenjem pokazala je interakciju vezanu uz spol (ženski) i to s obzirom na incidenciju svih nuspojava te ozbiljnih nuspojava.
Pharmacotherapeutic group: cardiac therapy, antiarrhythmics class III, ATC code: C01BD07
Farmakoterapijska skupina: pripravci koji djeluju na srce, antiaritmici skupine III, ATK oznaka: C01BD07.
• QTc Bazett interval ≥500 milliseconds
• QTc-interval ≥ 500 milisekundi prema Bazettovoj formuli
Since antiarrhythmic medicinal products may be ineffective or may be arrhythmogenic in patients with hypokalaemia, any potassium or magnesium deficiency should be corrected before initiation and during dronedarone therapy.
Budući da antiaritmici mogu biti nedjelotvorni ili aritmogeni u bolesnika s hipokalijemijom, bilo kakav nedostatak kalija ili magnezija treba korigirati prije početka i tijekom liječenja dronedaronom.
In the pooled data from EURIDIS and ADONIS as well as in the individual trials, dronedarone consistently delayed the time to first recurrence of AF/AFL (primary endpoint).
Objedinjeni podaci iz ispitivanja EURIDIS i ADONIS, kao i iz pojedinačnih ispitivanja, pokazuju da dronedaron dosljedno odgađa vrijeme do prvoga recidiva FA/UA (primarna mjera ishoda).
In 2-year oral carcinogenicity studies, the highest dronedarone dose administered for 24 months was 70 mg/kg/day in rats and 300 mg/kg/day in mice.
U dvogodišnjem ispitivanju kancerogenosti peroralnih doza najveća doza dronedarona primjenjivana tijekom 24 mjeseca bila je 70 mg/kg na dan u štakora i 300 mg/kg na dan u miševa.
The active substance is dronedarone.
Djelatna tvar je dronedaron.
• Patients with liver and lung toxicity related to the previous use of amiodarone
• Bolesnici s toksičnim oštećenjem jetre i pluća povezanim s prethodnom primjenom amiodarona
How to take MULTAQ
Kako uzimati MULTAQ
Maintenance of sinus rhythm
Održavanje sinusnog ritma
In patients who were taking amiodarone, an ECG was to be performed about 4 hours after the first administration to verify good tolerability.
U bolesnika koji su uzimali amiodaron trebalo je napraviti EKG otprilike 4 sata nakon prve primjene kako bi se potvrdila dobra podnošljivost.
If serum creatinine continues to rise then consideration should be given to further investigation and discontinuing treatment.
Ako razine kreatinina u serumu nastave rasti, treba razmotriti provođenje dodatnih pretraga i prekid liječenja.
Heart, lung and blood tests
Pretrage srca, pluća i krvi
• other medicines for high blood pressure, for chest pain caused by heart disease, or other heart problems, such as verapamil, diltiazem, nifedipine, metoprolol, propranolol or digoxin,
• druge lijekove za visoki krvni tlak, za bolove u prsištu uzrokovane bolešću srca ili za druge tegobe sa srcem, kao što su verapamil, diltiazem, nifedipin, metoprolol, propranolol ili digoksin,
MULTAQ is not recommended during pregnancy and in women of childbearing potential not using contraception.
Ne preporučuje se koristiti lijek MULTAQ tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
• terfenadine (a medicine for allergies),
• terfenadin (lijek za alergije),
Available pharmacodynamic/toxicological data in animals have shown excretion of dronedarone and its metabolites in milk.
Dostupni farmakodinamički/toksikološki podaci u životinja pokazuju da se dronedaron i njegovi metaboliti izlučuju u mlijeko.
Administration of dronedarone to patients receiving digoxin will bring about an increase in the plasma digoxin concentration and thus precipitate symptoms and signs associated with digoxin toxicity.
Primjena dronedarona u bolesnika koji primaju digoksin dovest će do povišenja koncentracija digoksina u plazmi te tako izazvati simptome i znakove povezane s toksičnošću digoksina.
White, oblong shaped tablets, engraved with a double wave marking on one side and “4142”code on the other side.
Bijele, duguljaste tablete s utisnutom dvostrukom valovitom oznakom na jednoj i oznakom „4142” na drugoj strani.
Bradycardia (see sections 4.3 and
bradikardija (vidjeti dijelove 4.3 i 4.4)
The median time from randomised to first AF/AFL recurrence in the dronedarone group was 116 days, i.e. 2.2-fold longer than in the placebo group (53 days).
U skupini koja je primala dronedaron medijan vremena od randomizacije do prvog recidiva FA/UA iznosio je 116 dana, tj. bio je 2,2 puta dulji nego u skupini koja je primala placebo (53 dana).
Hepatotoxicity are concerned by the additional minimization measures.
• hepatotoksičnost su obuhvaćeni dodatnim mjerama minimizacije rizika.
The digoxin dose should be reduced by approximately 50%, serum levels of digoxin should be closely monitored and clinical and ECG monitoring is recommended.
Doza digoksina mora se smanjiti za približno 50%, moraju se pažljivo pratiti koncentracije digoksina u serumu, a preporučuje se i kliničko i EKG praćenje.
• dabigatran (a medicine for prevention of blood clot formation).
• dabigatran (lijek za sprječavanje stvaranja krvnih ugrušaka).
In clinical studies, bradycardia was more frequently observed when dronedarone was given in combination with beta-blockers.
U kliničkim je ispitivanjima bradikardija primijećena češće kada se dronedaron primjenjivao u kombinaciji s beta-blokatorima.
• change in the results of blood tests used to check your liver function.
• promjene u nalazima krvnih pretraga kojima se ispituje funkcija jetre.
MULTAQ is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF).
MULTAQ je indiciran za održavanje sinusnog ritma nakon uspješne kardioverzije u odraslih, klinički stabilnih bolesnika s paroksizmalnom ili perzistentnom fibrilacijom atrija (FA).
No decreases in ethinylestradiol and levonorgestrel were observed in healthy subjects receiving dronedarone (800 mg twice daily) concomitantly with oral contraceptives.
Nije opaženo smanjenje razine etinilestradiola ni levonorgestrela u zdravih ispitanika koji su dronedaron (800 mg dvaput na dan) primali istodobno s oralnim kontraceptivima.
Patients with permanent atrial fibrillation
Bolesnici s permanentnom fibrilacijom atrija:
Onset of dyspnoea or non-productive cough may be related to pulmonary toxicity and patients should be carefully evaluated clinically.
Pojava dispneje ili neproduktivnog kašlja može biti povezana s toksičnim djelovanjem na pluća pa treba učiniti pažljivu kliničku procjenu bolesnika.
Since dronedarone is a weak inhibitor of CYP 2D6 in humans, it is predicted to have limited interaction on antidepressant medicinal products metabolised by CYP 2D6.
Budući da je dronedaron slab inhibitor CYP2D6 u ljudi, pretpostavlja se da će imati ograničenu interakciju s antidepresivima koji se metaboliziraju pomoću CYP2D6.
Observations were increased incidence of mammary gland tumors in female mice, histiocytic sarcomas in mice and hemangiomas at the mesenteric lymph node level in rats, all at the highest tested dose only (corresponding to an exposure of 5 to 10 times that of the human therapeutic dose).
Primijećena je povećana incidencija tumora mliječne žlijezde u ženki miševa, histiocitnih sarkoma u miševa i hemangioma mezenterijskog limfnog čvora u štakora, i to samo pri najvećim ispitivanim dozama (što odgovara izloženosti 5 do 10 puta većoj od one koja se postiže primjenom terapijske doze u ljudi).
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicine.
Ako Vam je liječnik rekao da ne podnosite neke šećere, obratite se liječniku prije uzimanja ovog lijeka.
The mean exposure of the N-debutyl metabolite is decreased by 47% (see section 4.2).
N-desbutil metabolitu manja je za 47% (vidjeti dio 4.2).
The Prescriber Guide should display information to help physician assess whether the patient is eligible for MULTAQ prescription and whether the patient remains within the prescribing information.
Vodič za liječnike propisivače mora sadržavati informacije koje će liječniku pomoći ocijeniti je li bolesnik prikladan kandidat za liječenje lijekom MULTAQ i ostaje li unutar okvira informacija o lijeku.
EU/1/09/591/001 - cartons of 20 film-coated tablets EU/1/09/591/002 - cartons of 50 film-coated tablets EU/1/09/591/003 - cartons of 60 film-coated tablets EU/1/09/591/004 - cartons of 100 x 1 film-coated tablets
EU/1/09/591/001 - kutija s 20 filmom obloženih tableta EU/1/09/591/002 - kutija s 50 filmom obloženih tableta EU/1/09/591/003 - kutija sa 60 filmom obloženih tableta EU/1/09/591/004 - kutija sa 100 x 1 filmom obloženom tabletom
Effect of dronedarone on other medicinal products
Učinak dronedarona na druge lijekove
After oral administration, approximately 6% of the labelled dose is excreted in urine mainly as metabolites (no unchanged compound excreted in urine) and 84% are excreted in faeces mainly as metabolites.
Nakon peroralne primjene približno 6% deklarirane doze izlučuje se mokraćom uglavnom u obliku metabolita (mokraćom se ne izlučuje spoj u neizmijenjenu obliku), a 84% doze izlučuje se fecesom uglavnom u obliku metabolita.
Calcium antagonists
Antagonisti kalcija
The recommended dose is 400 mg twice daily in adults.
Preporučena doza za odrasle je 400 mg dvaput na dan.
Dronedarone reduced the incidence of cardiovascular hospitalisation or death from any cause by 24.2% when compared to placebo (p<0.0001).
Dronedaron je smanjio incidenciju hospitalizacije zbog kardiovaskularnih razloga odnosno smrti zbog bilo kojeg uzroka za 24,2% u usporedbi s placebom (p<0,0001).
Dronedarone could increase plasma concentrations of immunosupressants (tacrolimus, sirolimus, everolimus and cyclosporine).
Imunosupresivi Dronedaron bi mogao povećati koncentracije imunosupresiva (takrolimus, sirolimus, everolimus i ciklosporin) u plazmi.
If this applies to you (or you are not sure), please talk to your doctor or pharmacist before taking MULTAQ.
Ako se ovo odnosi na Vas (ili niste sigurni), razgovarajte s liječnikom ili ljekarnikom prije nego što uzmete MULTAQ.
The most common reasons for discontinuation of therapy with dronedarone were gastrointestinal disorders (3.2% of patients versus 1.8% in the placebo group).
Najčešći razlog prekida liječenja dronedaronom bili su gastrointestinalni poremećaji (3,2% liječenih bolesnika naspram 1,8% ispitanika u skupini koja je primala placebo).
The pharmacological action of dronedarone may induce a moderate QTc Bazett prolongation (about 10 msec), related to prolonged repolarisation.
Farmakološko djelovanje dronedarona može izazvati blago produljenje QTc-intervala prema Bazettovoj formuli (otprilike 10 ms) povezano s produljenim vremenom repolarizacije.
• some medicines for reducing the cholesterol in your blood (such as simvastatin, lovastatin,
• neke lijekove za smanjenje razine kolesterola u krvi (kao što su simvastatin, lovastatin, atorvastatin ili rosuvastatin),
• inflammation of blood vessels (vasculitis including leukocytoclastic vasculitis).
• upala krvnih žila (vaskulitis uključujući leukocitoklastični vaskulitis)
It increases effective refractory periods (ERP) of the atrium, atrio-ventricular node, and ventricular ERP was slightly prolonged with a minimal degree of reverse frequency dependency.
Produljuje efektivno refrakterno razdoblje atrija, atrioventrikularnog čvora, a efektivno refrakterno razdoblje ventrikula bilo je blago produljeno uz minimalni stupanj obrnute frekvencijske ovisnosti.
Recurrences of AF (including absence of conversion) were more frequent in the dronedarone group, whereas premature study drug discontinuations due to intolerance were more frequent in the amiodarone group.
Recidiv FA (uključujući izostanak konverzije) bio je češći u skupini koja je primala dronedaron, dok je prijevremeni prekid primjene ispitivanoga lijeka zbog nepodnošenja bio češći u skupini koja je primala amiodaron.
Dronedarone does not affect the pharmacokinetics of clopidogrel and its active metabolite.
Dronedaron ne utječe na farmakokinetiku klopidrogela ni njegovog aktivnog metabolita.
• some medicines against blood clot formation such as warfarin,
• neke lijekove protiv stvaranja krvnih ugrušaka, kao što je varfarin,
The safety profile of dronedarone 400 mg twice daily in patients with atrial fibrillation (AF) or atrial flutter (AFL) is based on 5 placebo controlled studies, in which a total of 6,285 patients were randomised (3,282 patients received dronedarone 400 mg twice daily, and 2,875 received placebo).
Sigurnosni profil dronedarona u dozi od 400 mg dvaput na dan u bolesnika s fibrilacijom atrija ili undulacijom atrija temelji se na 5 placebom kontroliranih ispitivanja u kojima je randomizirano ukupno 6285 bolesnika (3282 bolesnika primala su dronedaron u dozi od 400 mg dvaput na dan, a 2875 bolesnika primala su placebo).
a Determined from Cox regression model b P-value of interaction between baseline characteristics and treatment based on Cox regression model c Calcium antagonists with heart rate lowering effects restricted to diltiazem, verapamil and bepridil
a Određeno na temelju Coxova regresijskog modela b P-vrijednost interakcije između početnih obilježja i liječenja na temelju Coxova regresijskog modela c Antagonisti kalcija koji utječu na usporavanje srčanog ritma ograničeni na diltiazem, verapamil i bepridil
Dronedarone has no significant potential to inhibit CYP 1A2, CYP 2C9, CYP 2C19, CYP 2C8 and CYP 2B6.
Dronedaron nema značajnog potencijala za inhibiciju CYP1A2, CYP2C9, CYP2C19, CYP2C8 ni CYP2B6.
There was a weak interaction between dronedarone and statins transported by OATP, such as rosuvastatin (which resulted in a mean 1.4-fold increase in rosuvastatin exposure).
Primijećena je slaba interakcija između dronedarona i statina koje transportira OATP, poput rosuvastatina (što je dovelo do srednjeg povećanja izloženosti rosuvastatinu od 1,4 puta).
There is limited information on the optimal timing to switch from amiodarone to dronedarone.
Podaci o optimalnom vremenu za prelazak s amiodarona na dronedaron su ograničeni.
After intravenous administration the plasma clearance of dronedarone ranges from 130 to 150 L/h.
Nakon intravenske primjene klirens dronedarona iz plazme kreće se u rasponu od 130 do 150 l/h.
As compared to placebo, dronedarone lowered the risk of first AF/AFL recurrence during the 12-month study period by 25% (p = 0.00007).
U usporedbi s placebom, dronedaron je tijekom 12-mjesečnog ispitivanja smanjio rizik od prvog recidiva FA/UA za 25% (p = 0,00007).
Patients should be advised to consult a physician if they develop or experience signs or symptoms of heart failure, such as weight gain, dependent oedema, or increased dyspnoea.
Bolesnike treba uputiti da se obrate liječniku ako razviju ili primijete znakove ili simptome zatajenja srca, poput povećanja tjelesne težine, hipostatskog edema ili pojačane dispneje.
After repeated administration of 400 mg twice daily, steady state is reached within 4 to 8 days of treatment and the mean accumulation ratio for dronedarone ranges from 2.6 to 4.5.
Nakon ponovljene primjene doze od 400 mg dvaput na dan stanje dinamičke ravnoteže postiže se unutar 4 do 8 dana liječenja, a srednji omjer kumulacije za dronedaron kreće se u rasponu od 2,6 do 4,5.
The reduction in cardiovascular hospitalisation or death from any cause was consistent in all subgroups, irrespective of baseline characteristics or medicinal products (ACE inhibitors or AIIRAs; beta-blockers, digitalis, statins, calcium antagonists, diuretics) (see figure 1).
Smanjenje incidencije hospitalizacije zbog kardiovaskularnih razloga ili smrti zbog bilo kojeg uzroka bilo je konzistentno u svim podskupinama, neovisno o početnim obilježjima ili lijekovima (ACE inhibitori ili antagonisti receptora angiotenzina II, beta-blokatori, digitalis, statini, antagonisti kalcija, diuretici) (vidjeti sliku 1).
In ESC and ACC/AHA/HRS guidelines dronedarone has a class IA recommendation in patients with paroxysmal/persistent AF and coronary artery disease.
U ESC i ACC/AHA/HRS smjernicama dronedaron ima preporuku klase IA u bolesnika s paroksizmalnom/perzistentnom fibrilacijom atrija i bolešću koronarnih arterija.
Monoamine Oxidases contribute partially to the metabolism of the active metabolite of dronedarone (see section 4.5).
Monoaminooksidaze djelomično pridonose metabolizmu aktivnog metabolita dronedarona (vidjeti dio 4.5).
This metabolite contributes to the pharmacological activity of dronedarone in humans.
Navedeni metabolit pridonosi farmakološkom djelovanju dronedarona u ljudi.
Patients should be carefully evaluated for symptoms of Congestive Heart Failure.
Bolesnike treba pažljivo pregledati kako bi se ustanovili mogući simptomi kongestivnog zatajenja srca.
Take the next dose when you are normally due to take it.
Uzmite sljedeću dozu po uobičajenom rasporedu.
The ANDROMEDA study was conducted in 627 patients with left ventricular dysfunction, hospitalised with new or worsening heart failure and who had had at least one episode of shortness of breath on minimal exertion or at rest (NYHA class III or IV) or paroxysmal nocturnal dyspnoea within the month before admission.
U kliničkom ispitivanju ANDROMEDA sudjelovalo je 627 bolesnika s disfunkcijom lijeve klijetke koji su hospitalizirani zbog novonastalog ili pogoršanja postojećeg zatajenja srca i koji su imali barem jednu epizodu nedostatka zraka kod minimalnog napora ili u mirovanju (NYHA stupanj III ili IV) ili paroksizmalne noćne dispneje unutar mjesec dana prije hospitalizacije.
Talk to your doctor or pharmacist before taking MULTAQ if
Obratite se svom liječniku ili ljekarniku prije nego što uzmete MULTAQ
Their co-administration is contraindicated (see section 4.3).
Njihova istodobna primjena je kontraindicirana (vidjeti dio 4.3).
Other moderate inhibitors of CYP3A4 are also likely to increase dronedarone exposure.
Ostali umjereni inhibitori CYP3A4 također će vjerojatno povećati izloženost dronedaronu.
Dronedarone is a multichannel blocker inhibiting the potassium currents (including IK(Ach), IKur, IKr, IKs) and thus prolonging cardiac action potential and refractory periods (Class III).
Dronedaron je višekanalni blokator koji inhibira protok kalija (uključujući IK(Ach), IKur, IKr, IKs) te tako produljuje srčani akcijski potencijal i refrakterna razdoblja (skupina III).
The pharmacokinetics of dronedarone and its N-debutyl metabolite both deviate moderately from dose proportionality: a 2-fold increase in dose results in an approximate 2.5- to 3.0-fold increase with respect to Cmax and AUC.
Farmakokinetika dronedarona i njegova N-debutil metabolita umjereno odstupa od proporcionalnosti dozi: dvostruko veća doza povećava Cmax i AUC približno 2,5 do 3 puta.
Dronedarone is contraindicated in patients with severe renal impairment (creatinine clearance (CrCl) <30 ml/min) (see section 4.3).
Dronedaron je kontraindiciran u bolesnika s teškim oštećenjem bubrežne funkcije (klirens kreatinina < 30 ml/min) (vidjeti dio 4.3).
• Inflammation of the lungs (including scarring and thickening of the lungs).
• Upala pluća (uključujući ožiljke i zadebljanja plućnog tkiva).
Women of child bearing potential and pregnancy
Žene reproduktivne dobi i trudnoća
While you are taking MULTAQ, your doctor may perform tests to check your medical condition and how the medicine is working for you.
Za vrijeme uzimanja lijeka MULTAQ liječnik može provoditi pretrage kako bi provjerio Vaše zdravstveno stanje i utvrdio kako lijek djeluje na Vas.